Top latest Five BRD4-targeted therapy ABBV-744 clinical data Urban news
In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Phase D, participants will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment right up until illness progression or perhaps the contributors are unable to tolerate the study drugs.- Participant eaten grapefruit or grapefruit products and solutions within 3 times